Skip to content
★ Sign in to follow
MD

Michelle Dipp

CEO
Tempest Therapeutics, Inc.
Total declarations
60
Company
1
▲ Purchases (35 ops.)
€7.4M
▼ Sales (0 ops.)
—

Latest filing published 03 Jun 2016 for Tempest Therapeutics, Inc., €2.7M.

Insider track record

Disclosed buys
35
Disclosed sells
0
Signal history

Closed purchases

Market purchases
35
Positive at T+90
15%
Median T+90
-22.2%

Based on 34 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Michelle Dipp: trading record in brief

Michelle Dipp is a declared insider of Tempest Therapeutics, Inc., with filings sourced from SEC (Form 4). In total, 60 filings cover trades dated from 13 August 2012 to 1 June 2016.

Every open-market trade on record is a purchase: 35 purchases worth €7.4M, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 22 share grants. Since January 2016: 23 purchases and no sales on the market.

The median purchase comes to €101k. Of 23 purchases, 23 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 34 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 15% of cases, with a median move of -22.2%. These figures describe past trades and do not predict future prices.

The latest filing, published on 3 June 2016, reports an open-market purchase of €2.7M in Tempest Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Michelle Dipp

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations59 total
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    3M USD47SEC
    425,000 shares@ US$7.0040.4% of flowCommon StockSEC:0001179110-16-025985:0
    Canonical exit: 30 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    157,200 USD43SEC
    20,000 shares@ US$7.862.1% of flowCommon StockSEC:0001179110-16-025106:0
    Canonical exit: 16 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    153,800 USD43SEC
    20,000 shares@ US$7.692.1% of flowCommon StockSEC:0001179110-16-024969:0
    Canonical exit: 14 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    151,200 USD43SEC
    20,000 shares@ US$7.562.0% of flowCommon StockSEC:0001179110-16-024969:1
    Canonical exit: 15 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    95,424 USD43SEC
    14,200 shares@ US$6.721.3% of flowCommon StockSEC:0001179110-16-024699:0
    Canonical exit: 10 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    39,928 USD43SEC
    5,600 shares@ US$7.130.5% of flowCommon StockSEC:0001179110-16-024699:1
    Canonical exit: 10 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    115,043 USD43SEC
    16,295 shares@ US$7.061.5% of flowCommon StockSEC:0001179110-16-024699:2
    Canonical exit: 11 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    152,800 USD43SEC
    20,000 shares@ US$7.642.0% of flowCommon StockSEC:0001179110-16-024522:0
    Canonical exit: 9 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    153,628 USD43SEC
    19,900 shares@ US$7.722.1% of flowCommon StockSEC:0001179110-16-024352:0
    Canonical exit: 8 Aug 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    207,886 USD40SEC
    21,700 shares@ US$9.582.8% of flowCommon StockSEC:0001179110-16-022185:0
    Canonical exit: 21 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    82,458 USD40SEC
    8,100 shares@ US$10.181.1% of flowCommon StockSEC:0001179110-16-022185:1
    Canonical exit: 21 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    276,900 USD40SEC
    30,000 shares@ US$9.233.8% of flowCommon StockSEC:0001179110-16-022185:2
    Canonical exit: 22 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    84,728 USD40SEC
    8,900 shares@ US$9.521.1% of flowCommon StockSEC:0001179110-16-022098:0
    Canonical exit: 19 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    225,981 USD40SEC
    21,100 shares@ US$10.713.0% of flowCommon StockSEC:0001179110-16-022098:1
    Canonical exit: 19 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    313,794 USD40SEC
    29,800 shares@ US$10.534.2% of flowCommon StockSEC:0001179110-16-022098:2
    Canonical exit: 20 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    232,142 USD40SEC
    29,800 shares@ US$7.793.1% of flowCommon StockSEC:0001179110-16-022004:0
    Canonical exit: 15 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    260,728 USD40SEC
    29,900 shares@ US$8.723.5% of flowCommon StockSEC:0001179110-16-022004:1
    Canonical exit: 16 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    137,280 USD38SEC
    17,600 shares@ US$7.801.9% of flowCommon StockSEC:0001179110-16-021775:0
    Canonical exit: 13 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    100,436 USD38SEC
    11,900 shares@ US$8.441.4% of flowCommon StockSEC:0001179110-16-021775:1
    Canonical exit: 13 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    164,923 USD40SEC
    21,729 shares@ US$7.592.3% of flowCommon StockSEC:0001179110-16-021775:2
    Canonical exit: 14 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    63,414 USD40SEC
    7,800 shares@ US$8.130.9% of flowCommon StockSEC:0001179110-16-021775:3
    Canonical exit: 14 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    995,490 USD35SEC
    132,732 shares@ US$7.5013.5% of flowCommon StockSEC:0001179110-16-021665:0
    Canonical exit: 9 Jun 2016 (T+90)
  • ▲
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    241,500 USD36SEC
    30,000 shares@ US$8.053.3% of flowCommon StockSEC:0001179110-16-021665:1
    Canonical exit: 12 Jun 2016 (T+90)
  • ●
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    0SEC
    15,452 sharesCommon StockSEC:0001179110-16-017507:0
  • ◆
    Chief Executive OfficerExecutivesTempest Therapeutics, Inc.
    0SEC
    4,635 sharesCommon StockSEC:0001179110-16-017276:0

25 of 59 declarations